Original paper

Comparative evaluation of severity of COVID-19 pneumonia on computed tomography of the chest in vaccinated and non-vaccinated individuals: an observational study

Manik Mahajan\textsuperscript{1,\textit{A,B,D,F}}, Vikrant Gupta\textsuperscript{1,\textit{A,B,D,F}}, Mohd Ilyas\textsuperscript{2,\textit{B,D,E}}, Kulbhushan Gupta\textsuperscript{1,\textit{D,E,F}}, Parveen Singh\textsuperscript{3,\textit{C,D,F}}

\textsuperscript{1}Government Medical College, Jammu, Jammu and Kashmir
\textsuperscript{2}Steadfast Healthcare Private Limited, Jammu, Jammu and Kashmir
\textsuperscript{3}Government Medical College, Kathua, India

Abstract

\textbf{Purpose:} Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus causing an infectious disease, coronavirus disease 2019 (COVID-19). Computed tomography (CT) of the chest plays a significant role in the diagnosis and prognosis of COVID-19 using computed tomography severity scoring (CT-SS). Numerous vaccines are being made available in the world to lessen the effect of the COVID-19 pandemic. The purpose of the current study is to compare the severity of COVID-19 pneumonia using CT-SS in COVID-19-positive vaccinated (Covishield/Oxford-AstraZeneca) and non-vaccinated individuals and to compare the final outcome wherever possible.

\textbf{Material and methods:} This observational study was carried out from March 2021 to April 2021. Forty vaccinated and 40 non-vaccinated RT-PCR-positive COVID-19 patients who underwent CT chest during the 4-12\textsuperscript{th} day of illness formed the material of the study. Semi-quantitative scoring was used, and CT-SS was calculated based on the extent of lobar involvement in all the patients. CT-SS was then compared between the vaccinated and non-vaccinated groups and the results analysed.

\textbf{Results:} CT scans were performed in 80 patients (40 patients each in the vaccinated and non-vaccinated groups). The majority of patients in the vaccinated group had mild (42.5\%) and moderate (37.5\%) CT-SS scores while the majority of patients in the non-vaccinated group had moderate (52.5\%) and severe (27.5\%) CT-SS score on chest CT. Also, no mortality was observed in the vaccinated group, with 2 deaths in the non-vaccinated group.

\textbf{Conclusions:} Covishield vaccine administration reduces the severity of COVID-19 pneumonia as compared to the non-vaccinated group, with a marked reduction in mortality.

\textbf{Key words:} COVID-19, computed tomography, chest, vaccine, RT-PCR.

Introduction

Coronavirus disease 2019 (COVID-19) is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 pneumonia refers to rapidly spreading acute respiratory syndrome [2]. COVID-19 shows variable clinical presentation, ranging from asymptomatic carriers to patients requiring assisted ventilation and intensive care unit (ICU) admissions with increased mortality [3]. The standard diagnosis of COVID-19 is made by using a reverse transcription-polymerase chain reaction (RT-PCR) assay, with reported sensitivities ranging from 42\% to 83\%, depending on symptom duration, viral load, and sample quality [4-8].

Imaging findings of COVID-19 pneumonia were first published in January 2020 and include bilateral lung involvement and ground glass opacities in the majority of patients [9]. Modest scientific evidence has demonstrated significant and constantly evolving value of computed...
tomography (CT) of the chest in the diagnosis and prognostication of COVID-19 pneumonia. However, substantial differences of opinion exist as to when and how chest CT should be used for clinical work-up or treatment decisions [10]. According to the Fleischner Society, imaging – particularly computed scanning – is a major tool if symptoms worsen or in an environment that is resource-constrained for RT-PCR [11]. Chest CT has 97% sensitivity in the diagnosis of COVID-19 pneumonia after a mean interval of 5 days [12]. Classical chest CT findings in COVID-19 pneumonia include ground glass opacities with bilateral, peripheral, and basal predominance with or without consolidation [13]. Central upper lobe predominance, masses, nodules, cavitations, lymphadenopathy, and pleural effusion are atypical findings observed on CT [14]. The COVID-19 Reporting and Data System (CO-RADS) provides a reporting format for the level of suspicion for pulmonary involvement of COVID-19 in non-contrast chest CT [10]. CT is also used to assess the severity of lung inflammation and involvement using quantitative and semi-quantitative parameters that evaluate the chest CT severity score (CT-SS) and provide an objective approach to easily and rapidly identify patients in need of hospital admission [15].

Numerous vaccines have been developed against SARS-CoV-2, with some of them being in clinical trials and some vaccines reporting more than 90% efficacy against COVID-19 in clinical trials. In India, 2 vaccines are currently being used to inoculate the population to prevent COVID-19, with Covishield being more commonly used than Covaxin. The vaccine is currently being administered as a 2-dose vaccine, with the second dose being administered at an interval of 6-8 weeks. The reported vaccine efficacy for AstraZeneca vaccine (combining dose groups) against the primary endpoint of COVID-19 occurring more than 14 days after the second dose is 70.4% [16]. However no or very limited literature is available regarding the severity of lung involvement in fully vaccinated (2 doses of Covishield vaccine) individuals positive for COVID-19. The purpose of the current study is to compare the severity of CT COVID-19 pneumonia in RT-PCR positive vaccinated and non-vaccinated individuals in the Indian population.

**Material and methods**

**Patients and groups**

This analytical cross-sectional study was carried out in the Department of Radio-Diagnosis and Imaging from March 2021 to April 2021. Forty non-vaccinated and 40 fully vaccinated (received both doses of Covishield) RT-PCR-positive COVID-19 patients who underwent chest CT formed the material of the study. Inclusion criteria included the following: a) COVID-19 RT-PCR-positive individuals above 45 years and less than 80 years of age, b) second dose of Covishield vaccine received at least 1 week before a positive RT-PCR test. Exclusion criteria included the following: a) patients on immunosuppressant therapy, b) markedly breathless patients who could not undergo CT due to lack of breath-hold, c) patients with pulmonary oedema and interstitial lung disease, d) vaccinated population less than 45 years of age (healthcare and frontline workers), and e) any pre-existing lung disease. Approval from the institutional ethics committee was obtained before conducting the study.

**Chest computed tomography scan**

Chest CT imaging was performed between 4th and 12th day of illness using multi-detector CT scanner (Siemens Somatom Sensation 64-slice scanner and Siemens Somatom Definition Flash 256 slice scanner). All the patients were examined in the supine position, and CT scans were acquired during a single inspiratory breath-hold. The scan was performed from the lung apex to the costophrenic angles. The CT acquisition parameters included: X-ray tube voltage 120 kVp and current 150 mAs; rotation time 0.5 seconds; pitch 1.0; section thickness 5 mm; intersection space 5 mm; additional reconstruction with a sharp convolution kernel; and a slice thickness of 1.0 mm.

**Chest CT-SS assessment**

The pulmonary involvement was assessed using a semi-quantitative scoring system to quantitatively estimate the pulmonary involvement. The CT-SS was calculated on the basis of the extent of lobar involvement [15]. Involvement of the lung lobes was visually calculated on a scale of 0-5, with 0 indicating no involvement, 1 indicating < 5% involvement, 2 indicating 5-25% involvement, 3 indicating 26-49% involvement, 4 indicating 50-75% involvement, and 5 indicating > 75% involvement (Table 1) [16]. The total severity score was the calculated as sum of the individual lobar scores, ranging from 0 (no involvement) to 25 (maximum involvement) [17,18] and classified as mild (score 7 or less), moderate (8-17), and severe (18 or more) [19]. All CT images were reviewed by 3 radiologists with more than 10 years of experience in a standard diagnostic system workstation. In case of any discrepancy in scoring, the findings of the most senior radiologist were accepted. All thin-section CT images were reviewed at

**Table 1. Lung involvement score on computed tomography**

| Lobar involvement (%) | Computed tomography severity score |
|-----------------------|----------------------------------|
| ≤ 5%                  | 1                                |
| 5-25%                 | 2                                |
| 26-49%                | 3                                |
| 50-75%                | 4                                |
| > 75%                 | 5                                |
with moderate CT-SS in the vaccinated group had score < 14 (11/15; 73.3%). In contrast, the majority of patients in the non-vaccinated group had moderate (21/40; 52.5%) and severe (11/40; 27.5%) disease (Tables 3 and 4). Mild CT-SS was observed in 17.5% cases in the non-vaccinated group. The patients were followed for up to 10 days after CT scan, with no mortality observed in the vaccinated group as compared to 2 deaths in the non-vaccinated group.

**Discussion**

At the end of 2019, Wuhan in China witnessed several cases of pneumonia-like conditions caused by a novel coronavirus. On 11 February 2020, this novel coronavirus was termed as SARS-CoV-2 by the international virus classification commission, and on the same day the disease caused by it was termed as COVID-19 by the World Health Organization (WHO) [20]. COVID-19 has rapidly and widely spread throughout the world with a significant impact on the socio-political situation and healthcare facilities. SARS-CoV-2 is a highly contagious virus and tends to spread via inhalation of respiratory aerosols, direct human contact, and via fomites. Although RT-PCR is the gold standard test in the diagnosis of COVID-19, it has variable reported sensitivities from 42 to 83% only [4–8], and one or more negative results do not completely rule out COVID-19. COVID-19 testing, however, has been constantly challenged by limited laboratory facilities and an inadequate supply of nucleic acid kits [21].

Imaging plays a key role in the assessment of severity of COVID-19 pneumonia. The commonest X-ray findings include bilateral lung involvement and ground glass opacities in the majority of patients. However, the absence of early changes on chest X-ray results in a large number of false negatives. Chest CT is a highly sensitive modality as compared to chest radiography, and it shows abnormal changes in the lung parenchyma in the early stages of disease [22,23]. Classical CT findings of COVID-19 pneumonia include multiple and asymmetrical ground glass opacities with bilateral, peripheral, and basal predominance with or without consolidation and bronchovascular thickening [13]. On CT, suspicion of COVID-19 infection is graded as follows: CO-RADS 1 – COVID-19 is highly unlikely (CT is normal or findings indicate a non-infectious disease), CO-RADS 2 – low suspicion of COVID-19 (CT findings are consistent with other infections), CO-RADS 3 – COVID-19 infection is indeterminate, CO-RADS 4 – level of suspicion is high and most CT findings are suspicious but not extremely typical or without a typical location and CO-RADS 5 – level of suspicion is high with typical CT findings [24]. Additional categories include technically insufficient examination (CO-RADS category 0) and RT-PCR-proven COVID-19 infection at the time of examination (CO-RADS category 6).

Until now no potential drugs are available to treat COVID-19, with the only treatment strategy being to relieve the patient’s symptoms. Various therapeutic treatments are still under trial and include antiviral drugs, antimalarial drugs, immunomodulators, and cell and plasma therapy. Numerous vaccines have been developed, which have variable efficacy in preventing the infection and reducing the risk of transmission, thereby limiting the pandemic. Two vaccines have been used in India: Covishield (Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19) and Covaxin (Whole-Virion Inactivated Vero Cell vaccine), with Covishield being the predominant one. Covishield is currently administered as a 2-dose vaccine, with the second dose administered at an interval of 6–8 weeks. The reported vaccine efficacy for AstraZeneca vaccine (combining dose groups) against the primary endpoint of COVID-19 occurring more than 14 days after the second dose is 70.4% [16]. However, limited or no literature is available demonstrating the role of Covishield in the evaluation of CT severity in COVID-19-positive individuals.

The majority of patients in our study were males, with a M : F ratio of 1.4 : 1. Similar results were obtained by Yang et al. in their study [25]. The commonest clinical symptoms of patients with COVID-19 in our study included fever, cough, and breathlessness.

In our study, CT findings were seen in 74 patients while normal scans was seen in 6 patients (5 in the vaccinated and 1 in the non-vaccinated group). GGO (97.5%) was the commonest abnormality observed on CT scan, followed by crazy paving and parenchymal consolidations (Table 2). Similar findings were observed by Hafez and Francone et al. in their studies [15,17]. The severity of disease on CT was classified as mild, moderate, or severe using the amount of lung opacification and calculating CT-SS in both the study groups [19]. The majority of patients in the vaccinated group had mild (42.5%) and moderate (37.5%) CT-SS score, while the majority of patients in the non-vaccinated group had moderate (52.5%) and severe (27.5%) CT-SS score. CT-SS was significantly higher in the non-vaccinated group as compared to the vaccinated group, thereby reflecting decreased lung involvement in vaccinated individuals. Also, the majority of patients with moderate CT-SS in the vaccinated group had score < 14 (11/15; 73.3%) as compared to the non-vaccinated group (12/21; 57.1%), further reflecting reduced lung parenchymal involvement in vaccinated individuals. Five cases in the vaccinated group had normal CT scan without any lung involvement, while no case in the non-vaccinated group had normal CT scan. Also, on short-term follow-up (up to 10 days), no mortality was observed in the vaccinated group as compared to 2 deaths in the non-vaccinated group.

CT-SS in COVID-19 pneumonia has paramount significance in assessing the extent of pneumonia (mild, moderate, and severe) and in predicting the dynamic changes
Table 2. Computed tomography (CT) findings in the study population (n = 80)

| CT finding                  | n (%)* |
|-----------------------------|--------|
| Ground glass opacities (GGO)| 72 (97.3) |
| Crazy paving                | 45 (60.8) |
| Parenchymal consolidations  | 29 (39.2) |
| Fibrosis                    | 25 (33.8) |
| Subpleural lines            | 22 (29.7) |
| Nodules                     | 12 (16.2) |
| Lymphadenopathy             | 7 (9.5)  |
| Pleural effusion            | 3 (4.1)  |

*Multiple findings

Results

Total of 80 nasopharyngeal swab RT-PCR-positive patients for COVID-19 formed the material of our study patients, including 40 patients each in vaccinated and non-vaccinated groups. Fever (91.3%) and cough (83.8%) were the commonest presenting symptoms in all patients followed by dyspnoea (68.8%) and fatigue (47.5%). The majority of patients in our study were males with a M : F ratio of 1.4 : 1.

CT chest was normal in 6 cases (5 cases in the vaccinated group and 1 case in the non-vaccinated group), while positive scans were observed in 74 patients. Ground glass opacities (GGO) (Figure 1A) were the most common patterns of disease (97.3%) followed by crazy-paving (Figure 1B) (60.8%) and parenchymal consolidations (Figure 2A) (39.2%) (Table 2). Other less common CT findings included fibrosis (33.8%) and subpleural lines (Figure 2B) (29.7%). The extent of lobar involvement, lesion distribution, and disease localization in both the lung parenchyma were observed, and CT-SS was calculated for both the groups.

Mean CT-SS in the vaccinated group was 0.34 ± 0.2, while in the non-vaccinated group it was 0.52 ± 0.2. The majority of patients in the vaccinated group had mild (score ≤ 7) disease (42.5%) followed by moderate (score 8-17) disease (37.5%) (Table 3). The majority of patients...
Severity of COVID-19 pneumonia in vaccinated and non-vaccinated individuals

Table 3. Distribution of severity of COVID-19 pneumonia among vaccinated and non-vaccinated individuals (n = 80)

| Status     | Normal | Mild | Moderate | Severe | Total | Odds ratio |
|------------|--------|------|----------|--------|-------|------------|
| Vaccinated | 5      | 17   | 15       | 3      | 40    | 0.006      |
| Non-vaccinated | 1 | 7    | 21       | 11     | 40    |            |
| Total      | 6      | 24   | 36       | 14     | 80    |            |

Table 4. Distribution of severity of COVID-19 pneumonia among vaccinated and non-vaccinated individuals (n = 80)

| Status     | Severe | Non-severe | Total | Odds ratio |
|------------|--------|------------|-------|------------|
| Vaccinated | 3      | 37         | 40    | 0.2        |
| Non-vaccinated | 11 | 29         | 40    |            |
| Total      | 14     | 66         | 80    |            |

of chest CT follow-up exams [15]. Also by assessing the severity of COVID-19 in the early stage, clinicians can accurately treat the disease [26] and prevent complications. A few other scoring systems are also available in scoring the severity of COVID-19 pneumonia. In one of such system, both lungs were divided into 20 regions and evaluated on CT, attributing scores of 0, 1, and 2, and therefore the sum of the individual could range from 0 to 40 points [25]. However, such a scoring system is time consuming and less practical to use when the flow of cases is very high.

So, we can conclude that Covishield vaccine administration significantly reduced the severity score of COVID-19 pneumonia on CT scan as compared to the non-vaccinated group. No mortality was observed in the vaccinated group as compared to 2 deaths in non-vaccinated group, thereby implying that vaccination may play a role in preventing deaths due to COVID-19. Also, the frequency of moderate and severe disease on CT was significantly lower in the vaccinated group.

Our study had some limitations. Although the effect of age as a confounding variable was removed by selecting a population above 45 years of age, other confounding variables such as co-morbidities (e.g. diabetes mellitus or hypertension) were not removed. The second limitation of this study was the limited sample size. This may be explained by the fact that the majority of the population over 45 years of age who underwent CT scans had already taken a single dose of vaccine and were not evaluated in the study. Thirdly, the amount of lung opacification on CT by CT-SS is indirect evidence of COVID-19 pneumonia burden and there was no histological confirmation of the findings in the study. So, further research is needed to identify the consistency of CT-SS in vaccinated and non-vaccinated individuals with COVID-19.

Conflict of interest

The authors report no conflict of interest.

References

1. Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs to know. Radiographics 2020; 40: 1848-1865.
2. Borghesi A, Zigliani A, Masciullo R, et al. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. Radiol Med 2020; 125: 461-464.
3. Thomas-Rüddel D, Winning J, Dickmann P, et al. Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. Anaesthetist 2021; 70 (Suppl 1): 1-10.
4. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol 2020; 92: 903-908.
5. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020; 296: E32-E40.
6. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323: 1843-1844.
7. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177-1179.
8. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25: 2000045.
9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
10. Prokop M, van Everdingen W, van Rees Vellinga T, et al. COVID-19 standardized reporting working group of the Dutch Radiological Society. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology 2020; 296: E97-E104.
11. Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multina-
tional consensus statement from the Fleischner Society. Chest 2020; 158: 106-116.

12. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging 2020; 101: 263-268.

13. Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 2020; 296: E55-E64.

14. Li X, Zeng W, Li X, et al. CT imaging changes of corona virus disease 2019 (COVID-19): a multi-center study in Southwest China. J Transl Med 2020; 18: 154.

15. Hafez MAF. The mean severity score and its correlation with common computed tomography chest manifestations in Egyptian patients with COVID-2019 pneumonia. Egypt J Radiol Nucl Med 2020; 51: 254.

16. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 2021; 397: 72-74.

17. Francone M, Iafrate F, Masic GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020; 30: 6808-6817.

18. Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020; 295: 715-721.

19. Saeed GA, Gaba W, Shah A, et al. Correlation between chest CT severity scores and the clinical parameters of adult patients with COVID-19 pneumonia. Radiol Res Pract 2021; 2021: 6697677.

20. Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10: 102-108.

21. Xiao SY, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring. J Med Virol 2020; 92: 464-467.

22. Paul NS, Roberts H, Butany J, et al. Radiologic pattern of disease in patients with severe acute respiratory syndrome: the Toronto experience. Radiographics 2004; 24: 553-563.

23. Ng MY, Lee EYP, Yang J, et al. Imaging profile of the COVID-19 infection: radiologic findings and literature review. Radiol Cardiotorac Imaging 2020; 2: e200034.

24. Prokop M, van Everdingen W, van Rees Vellinga T, et al.; COVID-19 Standardized Reporting Working Group of the Dutch Radiological Society. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19 – definition and evaluation. Radiology 2020; 296: E97-E104.

25. Yang R, Li X, Liu H, et al. Chest CT severity score: an imaging tool for assessing severe COVID-19. Radiol Cardiotorac Imaging 2020; 2: e200047.

26. Liu N, He G, Yang X, et al. Dynamic changes of chest CT follow-up in coronavirus disease-19 (COVID-19) pneumonia: relationship to clinical typing. BMC Med Imaging 2020; 20: 92.